 |
  |
The RPS conference 2010: Supporting
patient and professional decision making |
|
05-06
September 2010 |
|
How can
pharmacists best support patients in their
healthcare decisions? How can the profession be
supported in dealing with workplace and commercial
pressures while maintaining commitment to high
quality patient care? These are just some of the
issues that the Royal Pharmaceutical Society will
address at its new
conference in 2010. |
 |
|
|
|
|
|
 |
|
|
|
Pharmaceutical Stability
Testing Conference |
|
15th
and 16th
September 2010 |
Pressure to ensure that the
regulatory requirements for stability testing
are fulfilled, first time has
never been higher with the pharmaceutical industry as a whole
focusing on cutting margins and avoiding recalls. This
conference will feature a number of case studies where your fellow
peers highlight how they have approached different aspects of
Stability Testing to ensure efficiency and compliance.
|
|
|
|
|
|
 |
|
|
|
Biomarkers in Clinical Trials |
|
20th & 21st September 2010 |
|
SMi’s Biomarkers in Clinical
Trials conference
will present attendees with new concepts in
biomarker application as well as a comprehensive
review of recent developments. This unique event
will bring together academics and industry
professionals in order to provide a complete
picture. There will be a strong focus on using
biomarkers to bridge the gap between basic and
applied research in drug development.
|
|
|
|
|
|
 |
  |
|
Pharmaceutical
Pricing & Reimbursement in Turkey |
|
22nd September-2010 |
Turkey is an exciting,
high-growth potential market for
pharmaceutical manufacturers. Market access
however, is a complicated task in Turkey and
requires an excellent understanding of all
stakeholders' initiatives and views.
With a real intention to change the current
situation and shape advanced processes:
governmental bodies, the pharma industry and
leading academics are strongly advocating
initiatives such as HTA establishment and
increasing transparency of reimbursement
processes. Although the mission ahead is
complicated and is raising a number of
debates, it seems like the process has
started and pricing and reimbursement models
will be clearer in the short to medium
terms.
|
|
|
|
|
|
|
|
|
|
|
Biosimilars &
Biobetters |
|
22nd
& 23rd September 2010 |
Drawing
on the strength of SMi's successful
Generics, Supergenerics and
Patent Strategies
series, we are proud to present our inaugural
Biosimilars & Biobetters
conference
taking place on the
22nd
& 23rd
September 2010 in
London, UK. Book
before the 28th
May to save £300 on your place.
|
|
|
|
|
|
|
|
|
|
|
Advancing Clinical
Research in Turkey, Middle East & North Africa |
|
23th-24th September-2010 |
Industry sponsored
clinical trials are increasingly conducted
in emerging regions, due to escalating
competition and high costs in the more
established territories of North America and
Western Europe. As companies search for
advantages and new opportunities, factors
such as large and eager patient populations,
competitive trial budgets, and faster
recruitment rates at fewer sites are
prompting a fundamental geographic shift in
the location of studies.
|
|
|
|
|
|
|
|
 |
|
5th Annual Clinical
Outsourcing Partnerships In Central & Eastern Europe |
|
27th-28th September-2010 |
Central & Eastern Europe
continues to be a standout region for high quality
clinical research, with its well-trained
investigators and large patient populations. Due to
this popularity the clinical outsourcing environment
in CEE & Russia is becoming more complex and
difficult to navigate. This event will examine the
multitude of outsourcing practices being used in the
region today, as over the past 2-3 years several
powerful yet inherently different outsourcing
cultures have emerged in the region. These Preferred
Provider and Functional Service Provider models have
evolved in the region at varying levels of success
and they both bring with them a multitude of
opportunities and challenges for sponsors and
clinical solution providers alike.
|
|
|
|
|
|
|
|
|
|
|
Optimizing Early
Phase Oncology Studies to Accelerate Proof of
Concept |
|
29th-30th September-2010 |
When
running early clinical trials for experimental new
drugs across a range of therapeutic areas,
demonstrating "proof of concept" is a critical
milestone of the development process. It is at this
stage where exploratory studies become confirmatory
studies and there is a basis for studying the
efficacy in a larger population. From a business
perspective, showing proof of concept is also an
essential bargaining chip when negotiating licensing
agreements.
|
|
|
|
|
|
|
|
|
|
|
KOL: Knowledge
Leader Partnerships |
|
29th
& 30th September 2010 |
|
This
September, SMi offers the latest conference in
its highly regarded series on KOL management – KOL: Knowledge
Leader Partnerships.
Featuring presentations and panel debates from
the key players in the industry, alongside views
from agencies and the media, this conference is
a must-attend event to discover how best to
direct your Opinion Leader programme.
|
|
|
|
|
|
|
|
|
|
 |
|
Amorphous Pharmaceutical Materials
2010 |
|
27th
& 28th September 2010 |
Amorphous pharmaceutical materials
are now being recognised as an attractive
alternative route for solid state
development, partly due to the increasing
proportion of insoluble drug molecules in
development.
Owing to the lack of an ordered crystal
lattice, amorphous forms require minimal
energy and therefore offer enhanced
solubility, dissolution rate, and
bioavailability - properties which are all
integral to the effectiveness and success of
future medicines.
|
| |
| |
| |
| |
All rights reserved